Stay updated with breaking news from Exscientia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Exscientia (NASDAQ:EXAI – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Monday, Zacks.com reports. The brokerage currently has a $12.00 price target on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 1.69% from the stock’s current price. […]
Exscientia (NASDAQ:EXAI – Get Rating) issued its earnings results on Wednesday. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10), Fidelity Earnings reports. Shares of NASDAQ EXAI opened at $10.05 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.71 and […]
Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005906/en/ Recent advancements in the Company's pipeline
Exscientia plc This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005906/en/ Recent advancements in the Company’s pipeline,... | May 25, 2022
Company to host conference call and webcast on May 26, 2022 at 1:30 p.m. BST 8:30 a.m. ET Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing